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BACKGROUND: The mitogen-activated protein kinase (MAPK) phosphatases or dual specificity phosphatases (DUSPs) are a family of
proteins that catalyse the inactivation of MAPK in eukaryotic cells. Little is known of the expression, regulation or function of the
DUSPs in human neoplasia.
METHODS: We used RT–PCR and quantitative PCR (qPCR) to examine the expression of DUSP16 mRNA. The methylation in the
DUSP16 CpG island was analysed using bisulphite sequencing and methylation-specific PCR. The activation of MAPK was determined
using western blotting with phospho-specific antibodies for extra-cellular signal-related kinase (ERK), p38 and c-Jun N-terminal kinase
(JNK). The proliferation of cell lines was assessed using the CellTiter 96 Aqueous One assay.
RESULTS: The expression of DUSP16, which inactivates MAPK, is subject to methylation-dependent transcriptional silencing in Burkitt’s
Lymphoma (BL) cell lines and in primary BL. The silencing is associated with aberrant methylation in the CpG island in the
50 regulatory sequences of the gene blocking its constitutive expression. In contrast to BL, the CpG island of DUSP16 is unmethylated
in other non-Hodgkin’s lymphomas (NHLs) and epithelial malignancies. In BL cell lines, neither constitutive nor inducible ERK or p38
activity varied significantly with DUSP16 status. However, activation of JNK was increased in lines with DUSP16 methylation.
Furthermore, methylation in the DUSP16 CpG island blocked transcriptional induction of DUSP16, thereby abrogating a normal
physiological negative feedback loop that limits JNK activity, and conferred increased cellular sensitivity to agents, such as sorbitol and
anthracycline chemotherapeutic agents that activate JNK.
CONCLUSION: DUSP16 is a new epigenetically regulated determinant of JNK activation in BL.
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Burkitt’s Lymphoma (BL) is a highly aggressive B cell tumour often
presenting in extra-nodal sites or as acute leukemia (Blum et al,
2004). In the World Health Organization (WHO) classification,
three clinical variants of the disease are described. Endemic BL, the
most chemosensitive subtype, affects children and young adults
mainly in Africa and has been strongly correlated with Epstein–
Barr virus (EBV) infection. In contrast, sporadic BL occurs world-
wide and is predominantly EBV negative (Brady et al, 2008).
Immunodeficiency-associated BL occurs as a well-recognised
clinical feature of acquired immune deficiency syndrome. The
molecular hallmark of BL is the activation of the c-myc oncogene
through reciprocal chromosomal translocations that juxtapose
c-myc on chromosome 8 to the immunoglobulin (Ig) heavy chain
locus on chromosome 14 (80% of cases) or the k- or l-light chain
locus on chromosome 2 (10% of cases; Aldoss et al, 2008).
The mitogen-activated protein kinases (MAPKs) function in co-
ordinating cellular processes, such as proliferation and apoptosis.
There are at least three major groups of MAPK recognised. These
comprise the extra-cellular signal-related kinases (ERKs), Jun
N-terminal kinase (JNK) and a p38 MAPK (Boutros et al, 2008).
The MAPK phosphatases or dual specificity phosphatases (DUSPs)
are a family of proteins that catalyse the inactivation of MAPK in
eukaryotic cells and are so-called because of their ability to remove
phosphate groups from both threonine and tyrosine residues in
MAPK (Theodosiou and Ashworth, 2002). According to sequence
homology, substrate selectivity and sub-cellular localisation, the
DUSPs can be classified into distinct groups. Group I comprises
the nuclear, inducible DUSPs; DUSP1, DUSP2, DUSP4 and DUSP5
that target the primary MAPK, ERK, JNK and p38 MAPK. Group II
consists of cytoplasmic DUSPs that predominantly target ERK and
includes DUSP6, DUSP7 and DUSP9. On account of its unique
N-terminal structure, DUSP 10 is placed into group III. It is both
nuclear and cytoplasmic and targets p38 MAPK and JNK. Group
IV contains DUSP8 and DUSP16 that possess unique C-terminal
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sequences. In comparison to the other DUSP groups, relatively
little is known about the group IV DUSPs (Keyse, 2008). However,
DUSP16 is reported to inhibit MAPK activity in the order JNK
44 p38 4 ERK, with a preferential inhibition of JNK (Tanoue
et al, 2001). DUSP16 dynamically interacts with the JNK3 scaffold
protein b-arrestin 2 (Willoughby and Collins, 2005). The ability of
DUSPs to negatively regulate MAPK implies that they may
function as tumour suppressors (Theodosiou and Ashworth,
2002). DUSP16 may suppress the transformed phenotype of
rodent fibroblasts expressing bcr-abl, consistent with a tumour
suppressor function, although definitive evidence in support of
this hypothesis is lacking (Hoornaert et al, 2003).
There is now good evidence that epigenetic inactivation,
frequently through methylation-dependent transcriptional silen-
cing, is a common mechanism of inactivation of genes in cancer
(Stebbing et al, 2006; Esteller, 2007). However, only a small number
of transcriptionally silenced genes, such as p73 and fragile histidine
triad (FHIT), have been described in BL (Corn et al, 1999;
Lindstrom and Wiman, 2002; Hussain et al, 2004; Syed et al, 2006).
We have previously reported the use of subtraction PCR to
identify genes downregulated in B lymphomas and from these
studies observed methylation-dependent transcriptional silencing
of the polo-like kinase Snk/Plk2 (Syed et al, 2006), which showed a
strong, but not absolute, selectivity among B cell neoplasias, for
BL. In this study, we report the methylation-dependent transcrip-
tional silencing of a second gene, DUSP16, which demonstrates
a remarkable selectivity for BL.
MATERIALS AND METHODS
Cell lines and tissues
Burkitt’s lymphoma and EBV-immortalised B lymphoblastoid cell
lines (LCLs) were maintained in Roswell Park Memorial Institute
1640 (Gibco Invitrogen, Carlsbad, CA, USA) medium containing
10% foetal bovine serum. The following cell lines were used in our
study: nine BL cell lines (AW Ramos, BL2, BL41, Dante, DG75,
Mak-1, Mutu, Rael and Ramos); one mantle-cell lymphoma (MCL)
cell line (JUM2); one transformed follicular lymphoma (FL) cell
line (DOHH2); one diffuse large B-cell lymphoma (DLBCL) cell
line (LK6); and 10 LCLs (CR, IB4, JAC, JMV25, Otis, PD, GM12794,
GM13021, GM13022 and GM16756). The following carcinoma cell
lines were analysed for DUSP16 CpG island methylation: nine
epithelial ovarian cancer cell lines (1847, TR175, SKOV3, OVCAR3,
OVCAR433, OVCAR5, OVCAR8, JAMA2 and A2780) and 15 breast
cancer cell lines (MCF102, MDA MB157, MDA MB231, MDA
MB361, MDA MB436, MDA MB 453, MDA MB 468, MCF7, NCI,
GI101, T47D, BT20, CAL51, ZR75 and BT474).
For the activation of the JNK MAPK pathway, the following
treatments were used: sorbitol (Sigma-Aldrich Ltd., Dorset, UK) at
0.4 M for 30min; and cisplatin (Faulding Pharmaceuticals) at
50mgml1 from 5min to up to 8 h. When titrating the concentra-
tions of cisplatin, 1, 10, 20, 30 and 50 mgml1 were tested at 6 h
after the addition. For the stimulation of the ERK and p38 MAPK
pathway, the following treatments were used: 40% foetal calf serum
(Invitrogen, Paisley, UK) for 30min; epidermal growth factor at
0.1mgml1 for 10min; phorbol 12-myristate 13-acetate (Sigma-
Aldrich Ltd.) dissolved in dimethyl sulphoxide at 10 ngml1 for
10min. For the stimulation of the p38 MAPK pathway, anisomycin
(Sigma-Aldrich Ltd.) at 10 mgml1 for 30min was used.
Tissues were collected after local ethics committee’s approval.
Primary lymphomas were obtained as formalin-fixed, paraffin-
embedded biopsies. The diagnosis of malignant lymphoma was
made by morphological and immunohistochemical analysis
according to the WHO classification. Two expert haematopatho-
logists (KN and MB) reviewed the diagnosis of the NHL cases and
the sporadic and human immunodeficiency virus (HIV)-associated
BL. The histological types for the non-Hodgkin’s lymphoma (NHL)
samples were: diffuse large cell lymphoma (DLBCL, n¼ 10),
follicular lymphoma (FL, n¼ 10), mantle cell lymphoma (MCL,
n¼ 10), marginal zone lymphoma (MZL, n¼ 10) and BL: endemic
(n¼ 45), sporadic (n¼ 8) and HIV-associated (n¼ 4).
Genomic DNA was obtained using the DNeasy Mini kit (Qiagen,
Crawley, UK) or by proteinase K/phenol method.
Generation of cell lines ectopically expressing DUSP16
The DUSP16 expression plasmid, MSCVpuroDUSP16, used to
generate cell lines stably overexpressing DUSP16 has been
described previously (Hoornaert et al, 2003). One of the DG75
DUSP16 overexpressing lines was generated by electroporation.
For this, DG75 BL cells (10 106) were re-suspended in 800 ml
Roswell Park Memorial Institute 1640 medium mixed with 20 mg
MSCVpuroDUSP16 vector. Cells were electroporated at 975mFA
and 265V in a 4-mm cuvette, placed on ice for 1min and added
to 10-cm2 dish containing 9ml of pre-warmed Roswell Park
Memorial Institute 1640 medium. Puromycin (Sigma-Aldrich Ltd.)
selection 0.5mgml1 was added to the cells at 2 days after electro-
poration. Fresh medium and drugs were added every 2–3 days
until distinct colonies were formed. Other DG75 DUSP16 over-
expressing cell lines were generated again by electroporation,
but using the cell line nucleofector kit V from Amaxa (Amaxa
Biosystems, Koeln, Germany). A total of 2mg of MSCVpuroDUSP16
was transfected into 2 106 DG75 cells using solution V and
programme A-24. Cells were selected in 0.3mgml1 puromycin
1 day after electroporation.
Cell proliferation assay
Cell proliferation assays were carried out using the CellTiter
96 Aqueous One solution assay (Promega, Southampton, UK)
according to the manufacturer’s instructions, except that 10 ml of
Aqueous One solution was used instead of 20 ml and cells were
plated in 200 ml of culture medium instead of 100ml. Parental DG75
cells and DUSP16 overexpressing clones were plated in each well of
a 96-well plate. Cells were then either left untreated or exposed to
serial dilutions of sorbitol (0.025–0.8 M), cisplatin (3.125–
100mgml1) and doxorubicin (1.25–40 mgml1) and analysed at
various times after addition of the drug. Each treatment was
performed in quadruplicate for each cell line.
Bisulphite modification and methylation-specific PCR
Genomic DNA was extracted from cell pellets using the DNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions.
The DNA (0.5 mg) was modified by sodium bisulphite using the EZ
DNA Methylation Kit (Zymo Research, Orange, CA, USA). This
process converts unmethylated cytosine residues to uracil, whereas
methylated cytosine residues remain unchanged. Methylation-
specific PCR was then carried out to determine the methylation
status of DUSP16. Bisulphite-modified DNA was used as a
template for PCR with primers specific for methylated or
unmethylated alleles. CpGenome Universal Methylated DNA
(Chemicon Europe, Chandlers Ford, Hampshire, UK) and normal
human unmethylated DNA were used as positive and negative
controls, respectively, in each experiment.
The primer sequences were as follows:
For DUSP16:
50-CCACCCTTTCAAAAAACAACATAAAAACA-30 (unmethylated
forward),
50-AGTGTATTTATTGTGATTTTGTGTTTGGTT-30 (unmethylated
reverse),
50-ACCCTTTCGAAAAACGACGTAAAAACG-30 (methylated forward)
and
50-GTATTTATTGCGATTTCGCGTTCGGTC-30(methylated reverse).
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The PCR conditions were as follows: eight cycles of 951C for 2min,
601C for 30 s and 721C for 30 s were followed by 32 cycles of 951C
for 30 s, 601C for 30 s and 721C for 30 s and then a final extension
was carried out at 721C for 5min. The PCR products were resolved
by electrophoresis using 2% agarose gels, stained with ethidium
bromide, and visualised using a transilluminator.
Bisulphite sequencing
The bisulphite-modified genomic DNA (see above) was used as a
template in PCR. Two sets of primers were used to sequence the
DUSP16 CpG. The primer sequences were as follows:
For DUSP16: 50-TTATTTTTTAGAGAAGGAGAAGATAATATA-30
(forward 1) and 50-CCAAAACCACTTACTTTTAAAACC-30 (reverse 1),
50-TTTTTTGAGGGAATTGGGAG-30 (forward 2) and
50-TAATAAAAACAATCAAACCAAAACC-30 (reverse 2).
Reaction conditions for PCR were as follows: an initial incubation
at 951C for 5min was followed by 28 cycles of 951C for 30 s, 551C
for 30 s and 721C for 30 s and a final extension was performed
at 721C for 5min. The PCR products were purified using a PCR
purification kit (Qiagen), ligated into a TA-cloning vector
(Invitrogen), and transformed into top 10 Escherichia coli-
competent cells (Invitrogen). Colonies were grown on Luria–
Bertani agar plates under ampicillin and blue/white selection.
Plasmid DNA was used for sequencing with the BigDye Terminator
Cycle kit (PE Applied Biosystems, Warrington, UK) and reverse
primers. For each sample a minimum of six clones were
sequenced.
Methylation reversal
Cells were treated with 5 mM 50azacytidine (50AZA; Sigma-Aldrich
Ltd.) for 5 days followed by a combination of 50AZA and 300 nM
Trichostatin A (Sigma-Aldrich Ltd.) for a further 1–2 days. The
cells were split every 2–3 days with the addition of fresh drug.
After drug treatment, cells were collected for RT–PCR.
Analysis of gene expression
Total RNA was extracted using Trizol (Invitrogen). The comple-
mentary DNA was synthesized from 1 mg total RNA using oligo
(dT) primers and the ImProm-II Reverse Transcriptase Kit
(Promega). The expression of DUSP16 was analysed by RT–PCR
and real-time PCR (quantitative PCR). Primer sequences were as
follows:
For DUSP16: 50-GCACACCACCATTACATCATCG-30 (forward)
and
50- AACAGTCTGAAGAGAGAGAGGC-30 (reverse)
and the product size was 373 bp. The PCR conditions were as
follows: an initial denaturation at 951C for 5min was followed by
28 cycles of 951C for 30 s, 551C for 30 s and 721C for 30 s and a final
extension was carried out at 721C for 5min. Reactions were
resolved on 2% agarose gels and visualised on a transilluminator
after staining with ethidium bromide. The glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was co-amplified as a
control gene. The primer sequence for GAPDH is
50-TGAAGGTCGGAGTCAACGGATTT-30 (forward) and
50-GCCATGGAATTTGCCATGGGTGG-30 (reverse).
The PCR conditions were as follows: an initial denaturation at
951C for 5min was followed by 23 cycles of 951C for 1min, 591C
for 55 s and 721C for 45 s and a final extension was performed
at 721C for 7min.
Quantitative RT–PCR was performed in an ABI PRISM 7700
Sequence Detection System (PE Applied Biosystems, Weiterstadt,
Germany) using sequence-specific probes for DUSP16 and GAPDH
(PE Applied Biosystems). The TaqMan universal PCR master mix
(PE Applied Biosystems) was used and each sample was analysed
in triplicate.
Proteasome inhibition
The BL and LCL cells were either untreated or serum-starved
overnight and then treated with cisplatin (50mgml1) for 6 h alone
or with 30 mM of a proteasomal inhibitor (MG132; Sigma-Aldrich
Ltd.) for either 3 or 6 h.
Western blotting
To obtain protein from untreated exponentially growing cells, cells
were collected and lysed in lysis buffer (50mM Tris–HCl (pH 7.5),
250mM NaCl, 0.1% NP-40, 5mM EDTA, 50mM NaF, 1mM
phenylmethylsulphonyl fluoride with protease inhibitor cocktail;
Roche, Indianapolis, IN, USA). Cleared lysates were assayed for
protein concentration by using the Bio-Rad (Hemel Hempstead,
Hertis, UK) protein assay system and subjected to immuno-
blotting. Bound primary antibodies were detected with either
horseradish peroxidise-conjugated goat antirabbit antibody
or horseradish peroxidise-conjugated goat antimouse antibody
(Dako UK Ltd, Cambridgeshire, UK). Enhanced chemilumines-
cence western blotting detection reagents were purchased from
Amersham (Freiberg, Germany). The primary antibodies pur-
chased from Cell Signaling Technologies were used: anti-SAPK
(stress-activated protein kinase)/JNK MAPK, anti-p44/42 MAPK,
anti-p38 MAPK, anti-phospho-SAPK/JNK (Thr183/Tyr185), anti-
phospho-p44/42 MAPK (Thr202/Tyr204) and anti-phospho-p38
MAPK (Thr180/Tyr182). Anti-CtBP (C-terminal Binding Protein)
was a kind gift from Qinghong Zhang and has been described
previously (Wang et al, 2006). The mouse monoclonal antibody
PC10 was used for detection of proliferating-cell nuclear antigen
(1 : 10 000).
RESULTS
Transcriptional silencing of DUSP16 in Burkitt’s
Lymphoma
We examined expression of the type IV DUSP, DUSP16, in BL cell
lines using RT–PCR and quantitative PCR. Figure 1A shows
RT–PCR and quantitative PCR analysis of levels of DUSP16
mRNA (relative to Ramos in the quantitative PCR analysis).
DUSP16 was expressed in all EBV-immortalised LCLs we studied,
in each case at a higher level than in each of the BL cell lines
analysed. The DUSP16 mRNA was absent in the BL cell line, Rael,
and virtually undetectable in Dante and at higher levels in DG75
and Mutu cell lines (Figure 1A).
There is a CpG island in the 50 sequence of the DUSP16
gene (http://www.genome.ucsc.edu/cgi-bin/hgGateway), raising
the possibility that epigenetic silencing might underlie absent
expression of the gene. To address this possibility, we tested
whether expression of DUSP16 could be reactivated by demethyl-
ation. Cells were treated with 50AZA or the histone deacetylase
inhibitor, Trichostatin A, and expression was analysed by
RT–PCR. In BL cell lines lacking DUSP16 mRNA under the
limiting PCR conditions used, expression was increased by the
addition of 50AZA. A representative experiment with the Dante BL
cell line is shown in Figure 1B. In contrast, there was no change in
DUSP16mRNA expression in LCLs after the treatment with 50AZA.
We also analysed the expression and the effect of demethylation in
three additional NHL cell lines: JVM2 (MCL), DOHH2 (trans-
formed FL) and LK6 (DLBCL). In each cell line, expression of
DUSP16 was readily detectable in normally proliferating cells and
did not change after 50AZA and/or Trichostatin A treatment
(Figure 1C). The presence of a CpG island and reactivation of
expression in BL cell lines by 50AZA treatment is consistent with
methylation-dependent transcriptional silencing. Furthermore, the
absence of increased expression after 50AZA in non-BL NHL cell lines
implies that silencing is specific for BL. To investigate this, we
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performed bisulphite sequencing of the entire sequence of the CpG
island in several BL cell lines and in LCLs. These studies revealed the
presence of dense CpG methylation in each of the BL cell lines that
lacked DUSP16 mRNA. In contrast, there was no methylation in the
LCL that expresses DUSP16 (Figures 2A and B). In DG75 and Mutu,
which express an intermediate level of DUSP16 mRNA, there was
partial methylation in the CpG island. We designed primers for
methylation-specific PCR based on the sites of methylation revealed
by bisulphite sequencing (Figure 2B) and initially tested a panel of BL
cell lines and LCLs (Figure 1D). By methylation-specific PCR, the
majority of BL cell lines were methylated with both primer sets. Dante
and BL41 showed complete methylation (as evidenced by the absence
of amplification with the U primer pair. Mutu, DG75 and AW Ramos
were partially methylated, consistent with bisulphite sequencing data.
Of the tested cell lines, only BL2 was unmethylated. Taken together,
these results reveal a close correlation between low or undetectable
expression of DUSP16 and methylation in the CpG island.
DUSP16 methylation is specific for BL
These observations prompted us to analyse the methylation of
DUSP16 in primary B cell neoplasms. We analysed a series of
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Figure 1 Methylation-dependent silencing of DUSP16 expression in BL. (A) RT–PCR and qPCR analysis of DUSP16 mRNA expression in BL cell lines
and LCLs. Total RNA was prepared from exponentially growing cells as described in Materials and Methods section, and expression of DUSP16 and control
gene GAPDH mRNA analysed by RT–PCR (upper panel), and DUSP16 by qPCR (lower panel) as described in Materials and Methods section. In the qPCR
analysis, expression (±1 s.d.) is relative to Ramos. (B) The expression of DUSP16 is reactivated by demethylation in BL but is unaffected in LCL.
Exponentially growing cells were treated with 50azacytidine (50AZA) or Trichostatin A (TSA) as indicated. cDNA was prepared as described in Materials and
Methods section and expression of DUSP16 and the control gene GAPDH determined. C indicates control cells untreated with either 50AZA or TSA.
(C) DUSP16 mRNA is expressed and not epigenetically regulated in non-BL NHL. Expression of DUSP16 and GAPDH mRNA was analysed by RT–PCR in
JVM2, DOHH2 and LK6 and cell lines with or without exposure to 50AZA, TSA and 50AZA and TSA together as indicated. (D) The DUSP16 CpG island is
methylated in BL cell lines, but not LCLs. MSP was performed as described in Materials and Methods section, using independent primer pairs in upper and
lower panels. The figure shows unmethylated (U) and methylated (M) MSP reactions for each DNA sample, with control unmethylated (CU) and methylated
(CM) reactions as shown.
DUSP16 and Burkitt’s lymphoma
S Lee et al
268
British Journal of Cancer (2010) 103(2), 265 – 274 & 2010 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
B lymphomas, including DLBCL, FL, MCL, marginal zone
lymphoma and BL of endemic (n¼ 45), sporadic (n¼ 8) and
human immunodeficiency virus-associated (n¼ 4) sub-types
(Table 1). Consistent with results obtained in cell lines, there
was aberrant CpG methylation of DUSP16 in more than 50%
(27 out of 45 cases) of the primary endemic BL cases analysed
(Figure 2C). The methylation was also detected in two out of eight
sporadic cases and in two out of four human immunodeficiency
virus-associated cases, but there was no methylation in any other
NHL types (Table 1). We next examined methylation in solid
tumours. Methylation-specific PCR analysis of human breast and
ovarian carcinoma cell lines and malignant melanoma cell lines
revealed no detectable methylation in the DUSP16 CpG island,
despite reproducible methylation in BL cell lines (data not shown).
Together, these results reveal that methylation-dependent silencing
of DUSP16 shows specificity for BL.
DUSP16 methylation selectively deregulates stress-induced
JNK activation
Next, we tested whether cell lines with methylated DUSP16 exhibit
increased MAPK activity. In initial studies, we used immuno-
blotting to compare the constitutive activity of ERK, p38 and JNK
in cycling BL cell lines and LCLs. Although there were variations
7891011121314
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A C
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DG75
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CU MU1 32 4 5 6    7 8     9
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M
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B
Figure 2 Methylation in the DUSP16 CpG island in BL cell lines and primary BL, but not in LCLs. (A) Sample bisulphite sequencing trace, showing
complete methylation in Rael, partial methylation in DG75 and absence of methylation in the LCL. The arrows denote individual CpG dinucleotides
numbered from the start of the CpG island. (B) Summary of bisulphite sequencing analysis of DUSP16 CpG island in BL and LCL. The figure shows a
diagrammatic representation of the DUSP16 CpG island. CpG sites are shown as vertical lines. Methylated CpG dinucleotides are shown as black blocks,
unmethylated CpGs as open blocks. Five levels of methylation are indicated: 0¼ no black blocks; 1–25%¼ one black block; 25–50%¼ two black blocks;
50–75%¼ three black blocks; 75–100%¼ four black blocks. Positions of the MSP and bisulphite sequencing primers are indicated. The CpG island is almost
completely methylated in Rael, Dante and Ramos, partially methylated in DG75 and Mutu and unmethylated in the LCLs, consistent with expression of
DUSP16 mRNA in each cell line. (C) The DUSP16 CpG island is methylated in primary endemic BL. MSP was performed as described in Materials and
Methods section. The figure shows unmethylated (U) and methylated (M) MSP reactions for each DNA sample, with control unmethylated (CU) and
methylated (CM) reactions as shown.
Table 1 Methylation of the DUSP16 CpG island in B cell neoplasia
Cell line Origin EBV DUSP16 methylation (MSP)
AW Ramos Endemic + +/
BL2 Sporadic  
BL41 Sporadic  +
Dante Sporadic + +
DG75 Sporadic  +/
Mak-I Not known + +/
Mutu Endemic + +/
Rael Sporadic + +
Ramos Endemic  +/
Tissue Origin DUSP16 methylation (MSP)
DLBCL 0/10
FL 0/10
MCL 0/10
MZL 0/10
BL Endemic 27/45
BL Sporadic 2/8
BL HIV-associated 2/4
Abbreviations: BL¼ Burkitt’s lymphoma; DLBCS¼ diffuse large cell lymphoma;
DUSP16¼ dual specificity phophatase-16; EBV¼ Epstein –Barr Virus; FL¼ follicular
lymphoma; HIV¼ human immunodeficiency virus; MCL¼mantle cell lymphoma;
MSP¼methylation-specific PCR; MZL¼marginal zone lymphoma.
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between individual BL cell lines, constitutive levels of the MAPK
were not strikingly elevated in BL cell lines relative to LCL,
nor were they related to DUSP16 methylation status (Figures 3A, D
and 4A). We next tested whether DUSP16 methylation affected
dynamic activation of each of the MAPK, rather than constitutive
levels. We first sought to identify agents that selectively upregulate
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lines and LCL as indicated and ERK activity determined by western blotting as described in Materials and Methods section. (B) ERK phosphorylation is
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each of the MAPK pathways in B lymphocytes. The BL cell lines
and LCLs were serum-starved, then exposed to individual agents
and MAPK activity assessed. The phosphorylation of ERK was in
general not affected by serum or epidermal growth factor, but
there was a strong and consistent activation of ERK by the phorbol
ester phorbol 12-myristate 13-acetate (Figure 3B). However, there
was no detectable difference in phorbol 12-myristate 13-acetate-
induced phosphorylation of ERK between BL cells in which
DUSP16 is completely methylated (Rael, Dante and Ramos),
partially methylated (DG75) or LCL in which DUSP16 is
unmethylated (Figure 3C). For example, in DG75 cells that express
modest amounts of DUSP16, activation of ERK occurs to a
comparable degree as in Rael (undetectable DUSP16) and LCL
(high-level expression of DUSP16).
In the case of p38, there was modest elevation of constitutive
phosphorylated p38 levels in Ramos, but in other lines with
methylation-dependent silencing of DUSP16, such as Rael and
Dante, levels of phosphorylated p38 were not elevated relative to
LCL (Figure 3D). We tested whether anisomycin increased the
levels of phosphorylated p38, but there was no change in any of the
cell lines (Figure 3E). We then tested whether mitogens (serum,
epidermal growth factor and phorbol ester) increased p38
phosphorylation in LCL and BL cell lines, but there was no
striking increase in any of the other BL lines or LCL after exposure
to mitogens (Figure 3F).
Finally, we analysed JNK activity. To establish a time course of
JNK activation, we analysed Ramos BL cells that express only very
low levels of DUSP16 mRNA. Cells were serum-starved, exposed to
sorbitol and analysed for phosphorylated JNK using western
blotting. Phosphorylated JNK was detectable at 5min and reached
maximal levels at 60–120min (Figure 4B). We then examined the
phosphorylation of JNK in the panel of BL cell lines and LCL
treated with sorbitol. Each of the BL cell lines with methylation in
the DUSP16 CpG island exhibited a strong increase in JNK
activation when challenged with sorbitol, whereas there was only a
negligible increase in JNK activity in LCL (in which there is no
methylation in the DUSP16 CpG island (Figure 4C). These studies
thus imply a mechanistic association between methylation in the
DUSP16 CpG island and deregulated JNK signalling in response to
sorbitol.
Methylation blocks negative feedback induction of
DUSP16 expression
The activation of MAPK signalling under normal physiological
conditions results in the transcriptional upregulation of specific
DUSP gene expression that mediates a negative feedback loop and
terminates MAPK activity. We therefore asked whether methyla-
tion in the CpG island blocks the negative feedback transcriptional
upregulation of DUSP16 after activation of JNK signalling. We
initially performed time course analysis of transcriptional induc-
tion of DUSP16 in two independent LCLs (in which there is no
detectable methylation in the DUSP16 CpG island) treated with
sorbitol. There was upregulation of DUSP16 mRNA in both of the
LCLs analysed, with maximum levels attained by 1 h after sorbitol
exposure (see representative experiment, Figure 4D). We then
tested the induction of DUSP16 mRNA in the BL cell line panel in
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Figure 4 Methylation in the DUSP16 CpG island modulates inducible but not constitutive activation of JNK via inhibition of negative feedback
transcriptional upregulation of DUSP16 expression. (A) Constitutive JNK expression and activity is not elevated in BL relative to LCL and is unrelated to the
expression and methylation status of DUSP16. Protein lysates were prepared from exponentially growing BL cell lines and LCL as indicated and JNK
expression and activity were determined by western blotting as described in Materials and Methods section. (B) JNK phosphorylation is induced by sorbitol.
Ramos BL cells were serum-starved over night, then treated with 0.4 M sorbitol. Cells were collected at the indicated times (min) and total and
phosphorylated JNK determined by western blotting as described in Materials and Methods section. JNK phosphorylation is maximal at 120min after the
addition of sorbitol. (C) Sorbitol induces JNK activation in BL but not LCL. The indicated BL cell lines were serum starved overnight then challenged with
sorbitol. After 30min, JNK phosphorylation was determined by western blotting as described in Materials and Methods section. (D) Sorbitol induces
transcriptional upregulation of DUSP16. EBV-immortalised lymphoblastoid cells were exposed to 0.4M sorbitol and DUSP16 mRNA levels determined by
qPCR at the indicated times (h) as described in Materials and Methods section. Induced levels of DUSP16 mRNA are maximal at 1 h after addition of sorbitol.
Data shown are from a representative experiment. (E) Methylation blocks sorbitol-induced upregulation of DUSP16 mRNA. LCL and BL cell lines, as
indicated, were serum-starved overnight, then challenged with 0.4 M sorbitol (þ ) or not exposed to sorbitol (). DUSP16 mRNA levels were determined
by qPCR after 1 h as described in Materials and Methods section. Data shown are from a representative experiment.
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comparison to LCL. As previously observed, sorbitol caused a
rapid, approximately five-fold induction of DUSP mRNA in LCL1.
In the Rael and Dante BL cell lines, with dense methylation in the
DUSP16 CpG island, induction of DUSP16 mRNA was greatly
reduced in both cell lines relative to that seen in LCL (Figure 4E).
In Mutu and DG75, in which there is partial methylation in the
DUSP16 CpG island, there was a slightly stronger induction of
DUSP16 mRNA, but this too was reduced in magnitude relative
to the LCL (Figure 4E). These results reveal, therefore, that
methylation in the DUSP16 CpG island not only blocks
constitutive expression of DUSP16, but also inhibits the normal,
physiological transcriptional upregulation of DUSP16, which
occurs in response to stress such as that imposed by sorbitol.
These data suggest a potential role for DUSP16 in suppressing
activation of JNK signalling in response to stress, such as that
imposed by sorbitol, and imply that methylation in the DUSP16 CpG
island potentiates JNK signalling. As such, it was of obvious interest
to determine whether ectopic expression of DUSP16 could
re-establish negative feedback of JNK signalling in cells lacking
endogenous expression. To address this possibility, we attempted to
ectopically express DUSP16 in Rael, Dante and Ramos BL cell lines
in which expression of the endogenous gene is undetectable.
However, despite multiple, repeated attempts, it was not possible
to establish stable derivatives of any of these cell lines. We therefore
ectopically expressed DUSP16 in DG75 cells in which there is a
modest level of endogenous DUSP16 expression. We isolated several
clones in which DUSP16 expression was increased relative to
parental DG75 cells (Figure 5A). We wished to test JNK activation by
clinically used chemotherapeutic agents. We therefore investigated
whether cisplatin induced JNK in Dante BL cells and observed a
dose-dependent increase in JNK phosphorylation, confirming that
cisplatin activates JNK in BL (Figure 5B). Next, we compared
parental DG75 cells with daughter clones ectopically expressing
DUSP16. JNK was robustly activated by cisplatin with phosphory-
lated JNK detectable within 30min of exposure to cisplatin. In
contrast, phosphorylation of JNK was suppressed in the DUSP16
ectopically expressing cell line, phosphorylated JNK only becoming
detectable at 300min (Figure 5C).
DUSP16 regulates cellular sensitivity to cytotoxic
drugs in BL
Differences in JNK activation prompted us to test, in proliferation
assays, the sensitivity to cytotoxic agents of cell lines expressing
different levels of DUSP16. Sorbitol and doxorubicin demonstrated
clear, dose-dependent cytotoxicity to parental DG75 cells
(Figure 5D). Two independently derived clones of DG75 cells
ectopically expressing DUSP16 were reproducibly less sensitive to
sorbitol and doxorubicin than parental DG75 cells, showing a two
to four-fold increased resistance factor (Figure 5D). A similar
effect of DUSP16 expression on sensitivity to cisplatin was also
seen (data not shown). In some systems, JNK activation promotes
ubiquitin-dependent proteolysis of the transcriptional co-repres-
sor CtBP (Wang et al, 2006). If a similar mechanism operates in
BL, we would predict that the strongly enhanced activation of JNK
seen in cells with methylated DUSP16 would cause increased
degradation of CtBP. To test this possibility, we asked whether
levels of CtBP varied with the status of DUSP16 methylation and
hence inducibility of JNK activity. Dante BL cells (complete
methylation of DUSP16) and LCLs were treated for 6 h with
cisplatin in the presence or absence of the proteasome inhibitor
MG132 and levels of phosphorylated JNK and CtBP analysed.
Exactly as seen previously in Ramos and DG75 cells, cisplatin
induced phosphorylation of JNK, but there was no increase in JNK
phosphorylation in the LCL cells (Figure 5E). However, in both cell
lines, levels of CtBP decreased irrespective of DUSP16 status
and JNK phosphorylation. Furthermore, the decrease in CtBP
levels was not inhibited by MG132 (Figure 5E). Together,
these results imply that the enhanced activation of JNK seen in
DUSP16-deficient cells is not associated with enhanced proteolysis
of CtBP.
DISCUSSION
In this study, we show that the type IV DUSP, DUSP16, is subject
to methylation-dependent transcriptional silencing in BL, resulting
in the deregulation of JNK signalling. There are a large number of
DUSP genes in the human genome, but relatively little is known
regarding their involvement in cancer. The type I DUSP, DUSP1,
has been identified previously in studies using 50AZA to
pharmacologically reverse methylation, yet the CpG island was
reported to be unmethylated (Rauhala et al, 2005). Furthermore,
DUSP6 has been reported to be a target for methylation-dependent
silencing in pancreatic cancer (Xu et al, 2005). A single previous
study in prostate cancer has reported transcriptional down-
regulation of DUSP16 expression, but the mechanistic basis of
downregulation was not established (Kibel et al, 2004). The data we
present are, therefore, to the best of our knowledge, the first
demonstration of epigenetic silencing of a type IV DUSP gene in
human cancer. The ectopic expression of DUSP16 in fibroblasts
transformed by BCR-ABL reduces their transforming activity in
vivo accompanied by downregulation of BCR-ABL-induced
activation of JNK (Hoornaert et al, 2003). These studies support
the candidacy of DUSP16 as a tumour suppressor and are
consistent with our observations of a role for DUSP16 in
modulating the intensity and duration of JNK signalling.
Although DUSP16 is commonly methylated in BL cell lines and
endemic, sporadic and human immunodeficiency virus-associated
BL, methylation was almost never detected in EBV-immortalised
LCLs and the gene was abundantly expressed in these cells, implying
that methylation is specific to neoplasia. Moreover, we did not
detect methylation of DUSP16 in any cancer except BL, including
analysis of a panel of NHL cell lines and clinical cases of DLBCL, FL,
MCL and marginal zone lymphoma. As such, these results suggest a
clear specificity of DUSP16 methylation for BL. Furthermore,
analysis of the breast and ovarian cancer cell lines and malignant
melanoma cell lines also failed to detect methylation. Why is
methylation-dependent silencing of DUSP16 so tightly restricted to
BL and not observed in multiple other B lymphoma subtypes?
DUSP16 is a direct transcriptional target of B lymphocyte-induced
maturation protein, Blimp-1 (Magnusdottir et al, 2007), suggesting
that it may have a role in the normal developmental physiology of B
lymphocytes. It remains to be determined, however, whether
DUSP16 is downregulated in other cancers by genetic or other
mechanisms. In this respect, it is noteworthy that the DUSP16 gene
is located on chromosome 12p, an area of frequent chromosomal
loss in human tumours. In leukemia, recent data suggests that
deletions of 12p are a final event in mature cells (Wiemels et al,
2008). In non-small cell lung cancer, 12p deletions are an early
occurrence (Grepmeier et al, 2005).
We previously reported that the Polo-like kinase Snk/Plk2 was
subject to methylation-dependent transcriptional silencing at high
frequency in BL (Syed et al, 2006). Methylation of Snk/Plk2 was,
however, also detected in multiple other B cell neoplasias, whereas
methylation in DUSP16 seems to be tightly restricted to BL. We
have sought to address the mechanistic basis favouring the
selection of clones lacking DUSP16. Our results reveal that
methylation of DUSP16 correlates closely with deregulation of
JNK signalling. The activation of JNK signalling has been reported
to promote either cell death (Wang et al, 2006) or cell survival
according to different studies, although the reasons for such
differences in effect are not known. The data we present show that
JNK activation, at least in the context of BL, promotes apoptosis
and cytotoxicity in cells challenged with cytotoxic and/or oxidative
stress, as ectopic expression of DUSP16 reduced activation of JNK
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and this correlated with reduced sensitivity to doxorubicin,
sorbitol and cisplatin. One implication of the association of JNK
activation with cell death is that loss of JNK activation may
represent a mechanism of clinical drug resistance. Evidence in
acute myeloid leukemia cell lines to support this possibility has
recently been published (Lagadinou et al, 2008). It would be of
obvious interest to analyse the expression and epigenetic status of
DUSP16 in relapsed BL (at which time there are few active
chemotherapeutic options) to determine whether changes in
methylation in the DUSP16 CpG island occur with acquisition of
clinical drug resistance.
Promotion of apoptosis by activation of JNK has been shown in
some systems to result from enhanced degradation of the transcrip-
tional co-repressor CtBP (Wang et al, 2006). We tested whether
degradation of CtBP was increased in BL with DUSP16 methylation,
but we observed no evidence to support this hypothesis, CtBP
degradation being similar irrespective of DUSP16 status and
unaffected by treatment with the proteasome inhibitor MG132.
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Figure 5 DUSP16 expression modulates JNK activation and chemosensitivity in BL. (A) Ectopic expression of DUSP16 mRNA in DG75 cells transfected
with DUSP16 expression vectors. DG75 cells were stably transfected with a DUSP16 expression plasmid as described in Materials and Methods section.
DUSP16 mRNA levels were determined by RT–PCR (left panel) and qPCR (right panel) as described in Materials and Methods section. RT–PCR shows
parental () and DUSP16-transfected (þ ) cell line analysed for DUSP16 and the control gene GAPDH. The qPCR shows the log10 of DUSP16 mRNA levels
in one such clone of transfected cells (DUSP16/1) relative to parental DG75 cells ()±1 s.d. (triplicate analyses). (B) Cisplatin induces dose-dependent
activation of JNK in BL cells. Dante cells were exposed for 6 h to the indicated concentrations of cisplatin, after which cells were collected and total and
phosphorylated JNK levels determined by western blotting as described in Materials and Methods section. JNK phosphorylation increases with increasing
cisplatin concentration. (C) Ectopic expression of DUSP16 inhibits drug-induced activation of JNK. Parental DG75 cells and the clone DG75 DUSP16/1
were exposed to cisplatin (50 mgml1). Cells were collected at the indicated times (min) and the level of total and phosphorylated JNK determined by
western blotting. Activation of JNK is detectable at 60min in the parental cells, but not until 360min in the cells ectopically expressing DUSP16. (D) Ectopic
expression of DUSP16 reduces sensitivity of BL cells to cytotoxic drugs. Parental DG75 cells (black columns), together with two independent clones
ectopically expressing DUSP16 (denoted DG75/DUSP16/1 (grey columns) and DG75/DUSP16/2 (white columns), were grown to logarithmic phase, then
exposed to varying concentrations of sorbitol (mM) and doxorubicin (mgml1) as indicated. Proliferation was assessed using the CellTiter 96 Aqueous One
solution cell proliferation assay (Promega) according to the manufacturer’s instructions 48 h after addition of drug. Each point was determined in
quadruplicate. Data shown are mean±1 s.d. (E) CtBP degradation in drug-treated cells is not influenced by JNK phosphorylation or DUSP16 status. Dante
BL (in which DUSP16 is fully methylated) and LCLs were exposed to 50 mgml1 cisplatin for 6 h with or without MG132 for 3 or 6 h as shown, then
subjected to western blotting analysis of phosphorylated JNK and CtBP. JNK phosphorylation occurs only in Dante cells, whereas CtBP degradation is seen in
both cell lines and is unaffected by proteasome inhibition.
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In conclusion, we have identified DUSP16 as a new epigeneti-
cally regulated gene inactivation of which seems specific to BL. We
present evidence that expression of DUSP16 expression selectively
modulates the activation of JNK and influences cellular sensitivity
to chemotherapeutic agents.
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